GSK - GSK Share Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.

8 equities research analysts have issued 12-month price targets for GSK's stock. Their GSK share price forecasts range from GBX 1,245 to GBX 2,000. On average, they anticipate the company's share price to reach GBX 1,573.33 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for GSK or view top-rated stocks among Wall Street analysts.

GSK's stock was trading at GBX 1,437.60 at the start of the year. Since then, GSK stock has increased by 0.1% and is now trading at GBX 1,438.60.
View the best growth stocks for 2023 here.

GSK plc (LON:GSK) posted its earnings results on Wednesday, July, 29th. The company reported $56.90 EPS for the quarter. GSK had a trailing twelve-month return on equity of 31.31% and a net margin of 51.00%.

GSK declared a dividend on Wednesday, February 1st. Stockholders of record on Thursday, February 23rd will be paid a dividend of GBX 13.75 per share on Thursday, April 13th. This represents a dividend yield of 0.97%. The ex-dividend date is Thursday, February 23rd. The official announcement can be accessed at this link.
Read our dividend analysis for GSK.

GSK (LON:GSK) pays an annual dividend of GBX 61 per share and currently has a dividend yield of 4.43%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 5,495.50%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).

GSK trades on the London Stock Exchange (LON) under the ticker symbol "GSK."

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

One share of GSK stock can currently be purchased for approximately GBX 1,438.60.

GSK (LON:GSK) has a market capitalization of £58.84 billion and generates £29.32 billion in revenue each year. The company earns £4.46 billion in net income (profit) each year or GBX 1.11 on an earnings per share basis.

The company employs 90,096 workers across the globe.

GSK's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The official website for the company is www.gsk.com. The company can be reached via phone at +44-20-80475000.